Stockscreener 앱 받기
23.84
2.56%
0.595
시간 외 거래:
23.81
-0.03
-0.13%
전일 마감가:
$23.25
열려 있는:
$23.05
하루 거래량:
25,899
Relative Volume:
0.33
시가총액:
$1.30B
수익:
-
순이익/손실:
$-143.59M
주가수익비율:
-8.4431
EPS:
-2.8236
순현금흐름:
$-119.47M
1주 성능:
+0.17%
1개월 성능:
+32.52%
6개월 성능:
+24.69%
1년 성능:
+29.85%
1일 변동 폭
$21.50
$23.95
1주일 범위
$21.50
$24.41
52주 변동 폭
$11.51
$26.33
Pharvaris Nv Stock (PHVS) Company Profile
PHVS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PHVS
Pharvaris Nv
|
23.84 | 1.30B | 0 | -143.59M | -119.47M | -2.8236 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Pharvaris Nv Stock (PHVS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-11 | 개시 | Guggenheim | Buy |
| 2025-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-09-25 | 개시 | Wedbush | Outperform |
| 2023-08-15 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-10-05 | 개시 | Bryan Garnier | Buy |
| 2022-09-13 | 재개 | JMP Securities | Mkt Outperform |
| 2022-08-23 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-08-22 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-05-25 | 개시 | JMP Securities | Mkt Outperform |
| 2021-03-02 | 개시 | BofA Securities | Neutral |
| 2021-03-02 | 개시 | Morgan Stanley | Overweight |
| 2021-03-02 | 개시 | Oppenheimer | Outperform |
| 2021-03-02 | 개시 | SVB Leerink | Outperform |
모두보기
Pharvaris Nv 주식(PHVS)의 최신 뉴스
Understanding Stock Volatility in the Indian Market AI Driven Stock AlertsFree Risk Assessment Services - Autocar Professional
Pharvaris N.V. Stock Analysis and ForecastExceptional stock performance - PrintWeekIndia
What drives Pharvaris N.V. stock priceHigh-yield capital appreciation - PrintWeekIndia
What analysts say about Pharvaris N.V. stockAccelerated wealth building - Autocar Professional
Is Pharvaris N.V. a good long term investmentExceptional return forecasts - jammulinksnews.com
Property Share Investment Trust (544295) Hits 52 Week HighRapid wealth creation - Autocar Professional
What drives PTON stock priceBreakout stock performance - jammulinksnews.com
What drives iShares Gold Trust stock priceHigh-yield capital appreciation - jammulinksnews.com
NSE Quality Stocks Smart Investor Club PicksHigh-velocity gains - jammulinksnews.com
Best Renewable Stocks Smart Money Stock PicksPowerful growth strategies - jammulinksnews.com
What risks could impact Pharvaris N.V. stock performanceHigh Return Stock Alerts - Newser
Pharvaris: More Convenience, More Potency, And More Potential For Future HAE Success - Seeking Alpha
How To Trade (PHVS) - news.stocktradersdaily.com
Why Pharvaris N.V. stock attracts strong analyst attentionGrowth Optimized Stock Radar - beatles.ru
How Pharvaris N.V. stock performs during market volatilityFree Investment Community - Newser
What makes Pharvaris N.V. stock price move sharplyReal Time Alert Service - Newser
Pharvaris (NASDAQ:PHVS) Reaches New 1-Year High – Should You Buy? - Defense World
Pharvaris N.V. shares fall 4.98% in after-hours after updating key study data release timeline to Q4 2025. - AInvest
Pharvaris Expects to Release Topline Data From Phase 3 Hereditary Angioedema Study in Q4 - MarketScreener
Pharvaris NV expects Rapide-3 data announcement in Q4 2025 - MarketScreener
Pharvaris Pushes Key Phase 3 HAE Drug Results to Late 2025: What This Means for Oral Treatment - Stock Titan
Pharvaris N.V. (NASDAQ:PHVS) Receives $36.20 Consensus Price Target from Brokerages - Defense World
Pharvaris Announces Key Resolutions from Annual General Meeting - TipRanks
Breakthrough Clinical Data: New Oral Drug Could Transform HAE Treatment Landscape - Stock Titan
Is Pharvaris NV technically bullish or bearish? - MarketsMojo
HAE research continues to swell post-CSL Andembry win - BioWorld MedTech
(PHVS) Trading Advice - news.stocktradersdaily.com
Pharvaris presents new data on oral angioedema treatment at EAACI By Investing.com - Investing.com UK
Clinical Trial Results: Revolutionary Oral HAE Drug Prevents Attacks and Improves Quality of Life in 97.8% of Patients - Stock Titan
Analysts Set Pharvaris (NASDAQ:PHVS) Price Target at $36.20 - Defense World
Pharvaris (NASDAQ:PHVS) Now Covered by Analysts at Guggenheim - Defense World
Cantor Fitzgerald Weighs in on Pharvaris FY2026 Earnings - Defense World
Pharvaris (PHVS) Gains Buy Rating with Promising Market Potentia - GuruFocus
Bank of America Corp DE Increases Stake in Pharvaris (NASDAQ:PHVS) - Defense World
Guggenheim Initiates Coverage on Pharvaris With Buy Rating, $32 Price Target - marketscreener.com
Pharvaris (PHVS) Receives New Buy Rating and $32 Target from Gug - GuruFocus
Millennium Management LLC Trims Stake in Pharvaris (NASDAQ:PHVS) - Defense World
Pharvaris Schedules Key Shareholder Meeting: What HAE Treatment Investors Should Know - Stock Titan
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 14,838 Shares of Pharvaris (NASDAQ:PHVS) - Defense World
What is Leerink Partnrs’ Forecast for Pharvaris Q2 Earnings? - Defense World
Pharvaris (NASDAQ:PHVS) Given “Outperform” Rating at Wedbush - Defense World
Pharvaris (PHVS) Receives Continued "Outperform" Rating from Wedbush | PHVS Stock News - GuruFocus
Pharvaris (PHVS) Receives Continued "Outperform" Rating from Wed - GuruFocus
Citizens JMP reiterates Market Outperform rating for Pharvaris stock By Investing.com - Investing.com UK
Transcript : Pharvaris N.V.Special Call - marketscreener.com
Pharvaris Nv (PHVS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.87%
0.17%
자본화:
|
볼륨(24시간):